HC Wainwright & Co. Downgrades Arcturus Therapeutics Holdings (ARCT)
HC Wainwright & Co. has downgraded Arcturus Therapeutics Holdings (ARCT) stock. This indicates a revised, more cautious outlook from the financial firm regarding the company's future performance. Investors and market watchers should note this change in analyst sentiment.
HC Wainwright & Co. Downgrades Arcturus Therapeutics Holdings (ARCT)
HC Wainwright & Co. has downgraded its rating for Arcturus Therapeutics Holdings (ARCT). This downgrade indicates a less optimistic outlook from the financial firm regarding the company's stock performance. Investors will likely monitor ARCT's future developments and financial reports following this analyst action.
Responsive Playbooks and the ARCT Inflection
This article provides an in-depth analysis of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with specific entry, target, and stop-loss zones. The analysis also covers multi-timeframe signal strengths, support, and resistance levels for ARCT.
Hennion & Walsh Asset Management Inc. Purchases 161,910 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Hennion & Walsh Asset Management Inc. significantly increased its stake in Arcturus Therapeutics Holdings Inc. by purchasing an additional 161,910 shares, bringing its total ownership to 240,303 shares valued at approximately $1.47 million. Despite some analysts lowering price targets, Arcturus Therapeutics maintains a "Moderate Buy" consensus rating with an average target of $29.50. The biotechnology company, trading at around $7.85, recently reported a Q4 earnings miss with ($1.03) EPS and $7.2M in revenue, while institutional investors hold a substantial 94.54% of its shares.
ARCT SEC Filings - Arcturus Therape 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Arcturus Therapeutics Holdings Inc. (ARCT) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms. It highlights recent filings detailing the launch of KOSTAIVE, its approval in Japan, and insider share purchases. The platform uses AI to summarize lengthy reports and provides real-time EDGAR updates.
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78
This article reports a significant 27.17% decrease in the price target for Arcturus Therapeutics Holdings (ARCT), bringing it down to $25.78. This change indicates a potentially revised outlook on the company's future stock performance.
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78
This article reports that the price target for Arcturus Therapeutics Holdings (ARCT) has been decreased by 27.17% to $25.78. No further details or context regarding this change are provided within the article.
BTIG Maintains Arcturus Therapeutics Holdings (ARCT) Buy Recommendation
BTIG has reiterated its Buy rating on Arcturus Therapeutics Holdings (ARCT). While specific details of the analyst's price target or reasoning are not provided in this snippet, the endorsement suggests continued confidence in the company's prospects. This maintenance of a positive rating could influence investor sentiment and potentially impact ARCT's stock performance.
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78
This article reports a significant decrease in the price target for Arcturus Therapeutics Holdings (ARCT). The new price target is set at $25.78, representing a 27.17% reduction from its previous valuation.
Cathie Wood’s ARK sells Nvidia stock, buys Arcturus Therapeutics
Cathie Wood's ARK ETFs made significant trades on Friday, March 27th, 2026, selling off shares in technology giants like NVIDIA, Meta Platforms, AMD, and Teradyne. Concurrently, ARK increased its holdings in Arcturus Therapeutics, reflecting an active management strategy with reallocations towards emerging technologies and innovative companies. These movements follow earlier sales of Nvidia and Meta stock throughout the week.
Vanguard disaggregates holdings; reports 0 shares — Arcturus (ARCT)
The Vanguard Group has filed an amended Schedule 13G/A, reporting 0 beneficial shares of Arcturus Therapeutics Holdings Inc. (ARCT) following an internal realignment effective January 12, 2026. This filing indicates a procedural compliance shift where certain Vanguard subsidiaries will now report their beneficial ownership separately, rather than a market action involving the sale or purchase of ARCT stock. The change is in accordance with SEC Release No. 34-39538, clarifying that Vanguard no longer has beneficial ownership over securities held by these disaggregated units.
Understanding the Setup: (ARCT) and Scalable Risk
This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It describes institutional trading strategies for various risk profiles, including long, breakout, and short positions, and provides multi-timeframe signal analysis with support and resistance levels.
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
Arcturus Therapeutics is shifting its focus back to rare disease mRNA therapies after its COVID-19 vaccine received approval in over 30 countries. The company plans to advance its lead programs, ARCT-810 for OTC deficiency and ARCT-032 for cystic fibrosis, by seeking regulatory clarity and initiating further studies. Arcturus has cash runway into Q2 2028 but will require additional non-dilutive funding to complete Phase 3 trials for both programs.
Arcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial data
Arcturus Therapeutics' stock plummeted 50% following the announcement of disappointing Phase 1b interim data for its cystic fibrosis treatment, ARCT-032. The primary endpoint, sweat chloride reduction, showed insufficient improvement compared to placebo, leading to the company's decision not to advance to a Phase 2 study. Despite some positive trends in forced expiratory volume, the overall results halted the development of ARCT-032 for cystic fibrosis and triggered a significant stock decline.
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday
This article highlights four stock upgrades made by Wall Street analysts. Notably, an HSBC analyst upgraded BP PLC from Reduce to Hold, while analysts also upgraded Chipotle Mexican Grill Inc, Arm Holdings PLC, and SolarEdge Technologies Inc. The report details the specific rating changes and new price targets for each company.
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial
B. Riley Financial upgraded Arcturus Therapeutics (NASDAQ:ARCT) to a "strong-buy" rating despite mixed analyst views and recent missed quarterly earnings expectations. The clinical-stage biotech company, focused on mRNA medicines, maintains a "Moderate Buy" consensus rating with a target price of $29.50, and institutional ownership remains high at 94.54%.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a "Moderate Buy" consensus rating from thirteen brokerage firms, despite recent price target cuts from some analysts. The company's recent quarterly earnings missed expectations, with reported EPS of ($1.03) against an estimate of ($0.92) and revenue of $7.2 million versus an expected $14.32 million. Institutional investors own approximately 94.54% of the stock, with various firms recently adjusting their stakes.
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Benzinga reports on three significant analyst downgrades for Thursday. Raymond James downgraded Xponential Fitness (NYSE: XPOF) from "Strong Buy" to "Market Perform" after its shares closed at $5.67. Additionally, Evercore ISI Group downgraded CSX Corp (NASDAQ: CSX) from "Outperform" to "In-Line" with a raised price target, and DA Davidson downgraded Life360 (NASDAQ: LIF) from "Buy" to "Neutral" with a lowered price target.
B Riley Securities initiates coverage of Arcturus Therapeutics Holdings (ARCT) with buy recommendation
B Riley Securities has initiated coverage of Arcturus Therapeutics Holdings (ARCT) with a buy recommendation. This positive outlook suggests the firm sees potential for growth and value in Arcturus Therapeutics, a biotechnology company. Investors will likely watch for further details from B Riley Securities regarding their analysis and price targets for ARCT.
ARCT: B. Riley Securities Initiates Coverage with 'Buy' Rating | ARCT Stock News
B. Riley Securities has initiated coverage on Arcturus Therapeutics (ARCT) with a "Buy" rating and a price target of $22.00, according to analyst Mayank Mamtani. This new rating follows several varying analyst ratings for ARCT in recent months, with some firms maintaining or lowering their price targets. Arcturus Therapeutics is an RNA medicines company focusing on infectious disease vaccines and rare diseases.
Arcturus Therapeutics stresses importance of phased clinical trials in drug development
Arcturus Therapeutics highlights the critical role of phased clinical trials in bringing new gene and cell therapies from scientific discovery to patient treatments. The company emphasizes that each phase provides essential insights into safety and effectiveness, supported by ongoing collaborations to advance rare disease solutions and reports on financial standing and pipeline progress. This rigorous approach ensures promising treatments are thoroughly vetted before market entry.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 earnings call transcript
This is the Q4 2025 earnings call transcript for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT). The transcript details the company's financial results and discussions with management during the call.
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
Arcturus Therapeutics has completed three 28-day inhaled mRNA cohorts for its cystic fibrosis (CF) program, which were well-tolerated and showed early biological signals like reduced mucus plugging. The company is now preparing a 12-week Phase 2 study designed to more directly assess lung function using multiple measures, with an expanded enrollment to secure Class 1 CF patients in Europe and the Middle East. While an accelerated approval is not yet being pursued, the company's cash runway extends into Q2 2028, and it continues to advance its OTC and CSL programs.
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
Arcturus Therapeutics is preparing to launch a 12-week Phase 2 study for its inhaled mRNA cystic fibrosis (CF) program, following encouraging results from three 28-day cohorts that showed good tolerability and early biological signals. The upcoming study will focus on more precise lung function measurements and patient selection. Additionally, the company provided updates on its OTC deficiency program, CSL collaboration, and its cash runway extending into Q2 2028.
Citigroup Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price
Citigroup drastically cut its price target for Arcturus Therapeutics (NASDAQ:ARCT) from $66 to $21, while maintaining a "buy" rating, indicating a potential 189.7% upside. This reduction follows Arcturus missing Q4 earnings and revenue estimates, raising concerns about its near-term funding. Despite the pessimistic outlook from some analysts, the company's future hinges on clinical catalysts, including a Phase II trial for cystic fibrosis and regulatory clarity for ARCT-810 in 2026.
Arcturus Therapeutics to Attend Upcoming Investor Conference
Arcturus Therapeutics Holdings Inc. announced its participation in the Leerink Partners 2026 Global Healthcare Conference with a fireside chat on March 11, 2026. The company, a messenger RNA medicines specialist, focuses on liver and respiratory rare disease therapeutics and is known for developing KOSTAIVE®, the first approved self-amplifying mRNA COVID vaccine. Arcturus will provide a webcast link for the event on its investor relations website.
Arcturus Therapeutics to Attend Upcoming Investor Conference
Arcturus Therapeutics Holdings Inc. announced its participation in the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20 a.m. ET. The company, focused on messenger RNA medicines for rare liver and respiratory diseases, will host a fireside chat. A webcast link for the event will be available on Arcturus's investor relations website.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) discussed its Q4 2025 earnings, reporting an EPS miss. The call focused on the advancement of its mRNA therapeutic candidates, ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency, highlighting progress in clinical trials and regulatory interactions. The company also provided updates on its partnered COVID-19 vaccine program and its financial position, including a cash runway extended into Q2 2028.
Piper Sandler Maintains Overweight on Arcturus Therapeutics (ARCT) March 2026
Piper Sandler has maintained an "Overweight" rating on Arcturus Therapeutics (ARCT) as of March 4, 2026, signaling continued confidence despite a broader biotech sector reset and lowered price views for related entities. This decision is not a new upgrade or downgrade, but rather a reaffirmation of conviction for the stock. Citigroup also set an $8.00 price target for ARCT, while Meyka AI rates ARCT with a "B" grade, reflecting balanced opportunity with clinical and execution risks.
Arcturus Therapeutics Holdings ARCT Q4 Revenue Slide To US$7.2 Million Tests Growth Narrative
Arcturus Therapeutics Holdings reported Q4 FY 2025 revenue of US$7.2 million and a basic EPS loss of US$1.03, resulting in a net loss of US$29.1 million. The company's quarterly revenue has been declining significantly throughout FY 2025, from US$29.4 million in Q1 to US$7.2 million in Q4, raising concerns among bears despite a bullish outlook predicting 33.1% annual revenue growth and narrowing losses. The stock currently trades at a P/S of 2.6x, lower than industry peers, which bulls view as an opportunity while bears cite continued unprofitability and execution risks.
Citigroup Raises Price Target for Arcturus Therapeutics (ARCT) to $8.00 | ARCT Stock News
Citigroup has raised its price target for Arcturus Therapeutics (ARCT) from $7.00 to $8.00, maintaining a Neutral rating. This adjustment reflects a 14.29% increase for the biotech company, which specializes in therapeutic and vaccine development. Despite a series of previous price target reductions from various firms, the average analyst target price is $30.00, suggesting a significant upside.
Arcturus Therapeutics (ARCT) trims 2025 loss and extends cash runway into Q2 2028
Arcturus Therapeutics reported narrower losses and extended its cash runway into Q2 2028 despite weaker 2025 revenue, transitioning focus from COVID-19 related work to its mRNA rare disease pipeline. The company's net loss improved to $65.8 million, and it advanced its ARCT-032 cystic fibrosis program into a 12-week Phase 2 study. Revenue declined due to normalized COVID-19 collaboration activity, but operating expenses significantly decreased due to restructuring and lower program costs.
Arcturus Therapeutics 10-K: Revenue $82.0M; EPS not reported
Arcturus Therapeutics reported total revenue of $82.0 million for the year, a 46% decline primarily due to lower collaboration revenue. The company is transitioning towards commercial sales, with its product KOSTAIVE launched in Japan, the EU, and the UK. The report also detailed ongoing clinical programs and partnership dynamics.
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported first-quarter EPS of $-1.03, significantly missing the analyst estimate of $4.28. The company's revenue for the quarter also fell short at $7.2M, compared to the consensus estimate of $232.52M. Despite recent stock volatility, InvestingPro rates Arcturus Therapeutics Holdings Inc's financial health as "good performance."
Arcturus Therapeutics falls 5% on weak quarterly revenue
Arcturus Therapeutics Holdings Inc. reported a significant decline in fourth-quarter revenue, down 68% year-over-year to $7.2 million, primarily due to reduced collaboration revenue from CSL. Despite this, the company's net loss improved slightly, and it reduced operating expenses. Arcturus also highlighted progress in its rare disease therapeutic portfolio and extended its cash runway into the second quarter of 2028.
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) reported first-quarter EPS of $-1.03, significantly missing analyst estimates of $4.28 by $5.31. The company's revenue also fell short, coming in at $7.2 million compared to the consensus estimate of $232.52 million. Despite the earnings miss, Arcturus Therapeutics' stock has shown a 10.94% increase in the last three months, though it is down -48.93% over the past year.
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
Arcturus Therapeutics reported its financial results for Q4 and fiscal year 2025, highlighting a decrease in revenue and operating expenses compared to 2024. The company announced pipeline advancements, including plans to initiate a 12-week Phase 2 study for ARCT-032 in cystic fibrosis in H1 2026 and an expanded development strategy for ARCT-810 in OTC deficiency. Arcturus also noted an extended cash runway into Q2 2028 and ongoing legal proceedings.
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates
Arcturus Therapeutics Holdings Inc (ARCT) reported a significant earnings miss for the first quarter, with an EPS of $-1.03 against an analyst estimate of $4.28. The company's revenue also fell short of expectations, coming in at $7.2 million compared to the consensus estimate of $232.52 million. Despite this, InvestingPro rates Arcturus Therapeutics' financial health as "good performance."
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones
This article analyzes Arcturus Therapeutics Holdings Inc. (ARCT) using AI models to provide trading strategies. It highlights a mid-channel oscillation pattern and presents institutional strategies for long and short positions, along with multi-timeframe signal analysis indicating strong near-to-mid-term sentiment but a weak long-term outlook. The analysis also notes an exceptional risk-reward short setup with significant downside potential.
Arcturus Therapeutics Holdings Inc expected to post a loss of 71 cents a share - Earnings Preview
Arcturus Therapeutics Holdings Inc (ARCT) is anticipated to report a loss of 71 cents per share in its upcoming earnings. This forecast is based on information provided by Refinitiv and Reuters. The article serves as an earnings preview for investors following the company.
Arcturus Therapeutics Q2 2024 Financial Update
Arcturus Therapeutics announced its financial results for Q2 2024, reporting a significant revenue increase to $49.9 million, up from $10.5 million in Q2 2023, and a narrowed net loss. The company highlighted progress in its clinical pipeline, including an IND submission for ARCT-032 in cystic fibrosis, anticipated Q4 2024 data for ARCT-810, and the upcoming commercial launch of Kostaive® in Japan. Arcturus expects its cash runway to extend through Q1 2027, supporting ongoing development.
Technical Reactions to ARCT Trends in Macro Strategies
This article provides a technical analysis of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) trends and offers AI-generated trading strategies. It highlights a near-term weak sentiment, a mid-channel oscillation, and an exceptional risk-reward short setup. The analysis includes position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Potential 346% Upside with Innovative mRNA Therapies
Arcturus Therapeutics Holdings (ARCT) is a San Diego-based biotechnology firm focused on mRNA-based therapies, with a robust pipeline including treatments for infectious diseases, liver conditions, and cystic fibrosis. Despite current unprofitability and negative free cash flow typical of developmental biotechs, analysts project a significant 346.81% upside, with an average target price of $33.56, driven by confidence in its proprietary LUNAR and STARR mRNA technology platforms. The company's innovative approach in the promising field of mRNA therapeutics positions it as a high-risk, high-reward investment for those with a long-term outlook.
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Crosses Below Two Hundred Day Moving Average - What's Next?
Arcturus Therapeutics (NASDAQ:ARCT) stock recently fell below its two hundred day moving average, trading at $7.51 with a 200-day moving average of $11.80. Despite recent downgrades from several firms, MarketBeat indicates a consensus "Moderate Buy" rating and a $34.00 price target. The company has a market capitalization of $213.36 million, a negative P/E ratio, and high institutional ownership, with Millennium Management significantly increasing its stake.
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Arcturus Therapeutics Holdings Inc. announced it will release its financial results for the fourth quarter and full fiscal year ended December 31, 2025, after the market closes on Tuesday, March 3, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Arcturus is a commercial messenger RNA medicines company focusing on rare disease therapeutics and infectious disease vaccines.
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Arcturus Therapeutics Holdings Inc. announced it will release its financial results for the fourth quarter and full fiscal year ended December 31, 2025, after market close on Tuesday, March 3, 2026. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to provide a corporate update. Arcturus is a commercial messenger RNA medicines company focusing on rare diseases and infectious disease vaccines, known for developing the first self-amplifying mRNA COVID vaccine, KOSTAIVE®.
Balyasny reports no Arcturus Therapeutics (ARCT) stake in amended 13G/A
Balyasny Asset Management and its affiliated entities have filed an amended Schedule 13G/A, declaring they no longer hold a beneficial ownership stake in Arcturus Therapeutics Holdings Inc. (ARCT). As of December 31, 2025, they report owning 0 shares, representing 0.00% of the outstanding common stock, and have no voting or dispositive power. The filing confirms their holdings were in the ordinary course of business and not intended to influence company control.
Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating
Citi has lowered its price target for Arcturus Therapeutics Holdings Inc. (ARCT) to $7, while maintaining a neutral rating on the stock. This adjustment reflects a revised outlook on the company's valuation.
Arcturus cut to Neutral at Citi on data for mRNA candidate
Citi has downgraded Arcturus Therapeutics to a Neutral rating from Buy due to data for its mRNA candidate. This ratings change reflects a revised outlook from the analyst firm regarding the company's prospects following recent developments in its drug pipeline.
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit
Arcturus Therapeutics highlighted progress in its mRNA rare disease pipeline at the Guggenheim Biotech Summit. Key updates include advancing its inhaled mRNA candidate for cystic fibrosis (ARCT-032) to a 15 mg daily dose with promising early results, and plans for a larger Phase 2b study with improved endpoints. Additionally, the company is preparing for two FDA Type C meetings in H1 to discuss the regulatory path for its OTC deficiency program (ARCT-810), which has shown significant biomarker effects.
